The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3–4 CKD

References

• Centers for Disease Control and Prevention. National chronic kidney disease fact sheet; 2017 [accessed 2019 Jan 8]. https://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf
   Google Scholar
• Miller PD. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol. 2009;29(2):144–155.
   PubMed Web of Science ®Google Scholar
• Babitt JL, Lin HY. Mechanisms of anemia in CKD. JASN. 2012;23(10):1631–1634.
   Web of Science ®Google Scholar
• Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol. 2014;3(3):99.
   PubMedGoogle Scholar
• Fujii H. Association between parathyroid hormone and cardiovascular disease. Ther Apher Dial. 2018;22(3):236–241.
   PubMed Web of Science ®Google Scholar
• Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. JMCP. 2007;13(5):397–411.
   PubMed Web of Science ®Google Scholar
• Rix M, Andreassen H, Eskildsen P. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999;56(3):1084–1093.
   PubMed Web of Science ®Google Scholar
• Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008;74(6):721–731.
   PubMed Web of Science ®Google Scholar
• Jean G, Souberbielle J, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients. 2017;9(4):328.
   Web of Science ®Google Scholar
• Qunibi WY, Abdellatif A, Sankar S, et al. Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate? CN. 2010;73(04):276–285.
   Google Scholar
• Opko Inc. Rayaldee (extended-release calcifediol) prescribing information. [accessed 2018 Jan 18]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
   Google Scholar
• Khan S. Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am J Med Sci. 2007;333(4):201–207.
   PubMed Web of Science ®Google Scholar
• KDIGO. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59.
   Web of Science ®Google Scholar
• Sprague SM, Silva AL, Al-Saghir F, et al. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014;40(6):535–545.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Crawford PW, Melnick JZ, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016;44(4):316–325.
   PubMed Web of Science ®Google Scholar
• Martínez-Castelao A, Górriz JL, Portolés JM, et al. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. BMC Nephrol. 2011;12(1):53.
   PubMedGoogle Scholar
• Federal Registrar. Discount rates for cost-effectiveness analysis of federal programs. [accessed 2018 Feb 23]. https://www.federalregister.gov/documents/2015/01/29/2015-01616/discount-rates-for-cost-effectiveness-analysis-of-federal-programs
   Google Scholar
• Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care. 1989;27(Supplement):S233–S53.
   PubMedGoogle Scholar
• United States Renal Data System. USRDS 2015 annual report v1 – CH 2 identification and care of patients with CKD. [accessed 2018 Jul 20]. https://www.usrds.org/2015/view/v1_02.aspx
   Google Scholar
• LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J of Kidney Dis. 2005;45(6):1026–1033.
   PubMed Web of Science ®Google Scholar
• Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J of Kidney Dis. 2006;47(2):263–276.
   PubMed Web of Science ®Google Scholar
• De Boer IH, Sachs M, Hoofnagle AN, et al. Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease. Kidney Int. 2013;83(2):323–330.
   PubMed Web of Science ®Google Scholar
• Anwar N, Mahmoud MR. A stochastic model for the progression of chronic kidney disease. Int J Eng Res Appl. 2014;4(11):08–19.
   Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
   PubMed Web of Science ®Google Scholar
• Li XH, Feng L, Yang ZH, et al. Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: a systematic review and meta‐analysis. Nephrology. 2015;20(10):706–714.
   PubMed Web of Science ®Google Scholar
• Wang AY, Lam CW, Sanderson JE, et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr. 2008;87(6):1631–1638.
   PubMed Web of Science ®Google Scholar
• Lishmanov A, Dorairajan S, Pak Y, et al. Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease. Int Urol Nephrol. 2012;44(2):541–547.
   PubMed Web of Science ®Google Scholar
• West SL, Lok CE, Langsetmo L, et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res. 2015;30(5):913–919.
   PubMed Web of Science ®Google Scholar
• Stavroulopoulos A, Porter CJ, Roe SD, et al. Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrology. 2008;13(1):63–67.
   PubMed Web of Science ®Google Scholar
• Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75(1):88–95.
   PubMed Web of Science ®Google Scholar
• Asche C, Marx S, Kim J, et al. Impact of elevated intact parathyroid hormone on mortality and renal disease progression in patients with chronic kidney disease stages 3 and 4. Curr Med Res Opin. 2012;28(9):1527–1536.
   PubMed Web of Science ®Google Scholar
• Federal Reserve Bank of St. Louis. Consumer price index for all urban consumers: medical care, index 1982–1984 = 100, Monthly, seasonally adjusted; 2017 [accessed 2018 Feb 28]. https://fred.stlouisfed.org
   Google Scholar
• Truven Health Analytics, IBM Watson Health. Micromedex RED BOOK Online. [accessed 2018 Mar 18]. https://www.micromedexsolutions.com/home/dispatch/ssl/true
   Google Scholar
• Lee A, Belozerff V, Song X. Cost of treatment and clinical events for secondary hyperparathyroidism. Am J Pharm Benefits. 2013;5(2):e24–e35.
   Google Scholar
• United States Renal Data System. USRDS 2017 annual report v1, CH 6 health expenditures for persons with CKD. [accessed 2018 Jul 8]. https://www.usrds.org/2017/download/v1_c06_MedExp_17.pdf
   Google Scholar
• United States Renal Data System. 2018 annual data report reference tables, File K healthcare expenditures; 2018 [Accessed 2019 Jan 11]. https://www.usrds.org/reference.aspx
   Google Scholar
• Gorodetskaya I, Zenios S, Mcculloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68(6):2801–2808.
   PubMed Web of Science ®Google Scholar
• Davies EW, Matza LS, Worth G, et al. Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health Qual Life Outcomes. 2015;13(1):90.
   PubMedGoogle Scholar
• Fisher A, Srikusalanukul W, Davis M, et al. Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging. 2013;8:239–256.
   PubMed Web of Science ®Google Scholar
• Pilz S, Marz W, Wellnitz B, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008;93(10):3927–3935.
   PubMed Web of Science ®Google Scholar
• Kim DH, Sabour S, Sagar UN, et al. Prevalence of hypovitaminosis d in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol. 2008;102(11):1540–1544.
   PubMed Web of Science ®Google Scholar
• Alarcon T, Gonzalez-Montalvo JI, Hoyos R, et al. Parathyroid hormone response to two levels of vitamin D deficiency is associated with high risk of medical problems during hospitalization in patients with hip fracture. J Endocrinol Invest. 2015;38:1129–1135.
   PubMed Web of Science ®Google Scholar
• Giannini S, Sella S, Silva Netto F, et al. Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. J Bone Miner Res. 2010;25(4):841–848.
   PubMed Web of Science ®Google Scholar
• Shardlow A, McIntyre NJ, Fluck RJ, et al. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3. BMJ Open. 2017;7(8):e016528.
   PubMed Web of Science ®Google Scholar
• Schumock GT, Andress D, E Marx S, et al. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients. Curr Med Res Opin. 2008;24(11):3037–3048.
   PubMed Web of Science ®Google Scholar
• Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.
   PubMed Web of Science ®Google Scholar
• Weyland PG, Grant WB, Howie-Esquivel J. Does sufficient evidence exist to support a causal association between vitamin D status and cardiovascular disease risk? An assessment using Hill's criteria for causality. Nutrients. 2014;6(9):3403–3430.
   PubMed Web of Science ®Google Scholar
• Menezes FG, Abreu RM, Itria A. Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective. Brazilian J Nephrol. 2016;38(3):313–319.
   Google Scholar
• Rose M, Shepherd J, Harris P, et al. Etelcalcetide for treating secondary hyperparathyroidism: an evidence review group evaluation of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(11):1299–1308.
   PubMed Web of Science ®Google Scholar
• Nuijten M, Andress DL, Marx SE, et al. Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease Markov model. Clin Drug Investig. 2010;30(8):545–557.
   PubMed Web of Science ®Google Scholar
• EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–2494.
   PubMed Web of Science ®Google Scholar
• Hu X, Shang J, Yuan W, et al. Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease: a meta-analysis. Herz. 2018;43(6):518–528.
   PubMed Web of Science ®Google Scholar